 |
answer text |
<p>In January 2009, the National Institute for Health and Care Excellence (NICE) issued
supplementary advice to its appraisal committees on appraising treatments which may
be life-extending for patients, with short life expectancy, and which are licensed
for indications affecting small numbers of patients with incurable illnesses.</p><p>
</p><p> </p><p> </p><p>This sets out the following three criteria that must all be
satisfied for this supplementary advice to be applied:</p><p> </p><p>- the treatment
is indicated for patients with a short life expectancy, normally less than 24 months;</p><p>
</p><p>- there is sufficient evidence to indicate that the treatment offers an extension
to life, normally of at least an additional three months, compared to current NHS
treatment; and</p><p> </p><p>- the treatment is licensed or otherwise indicated, for
small patient populations.</p><p> </p><p> </p><p> </p><p>These criteria were developed
following public consultation and set out the circumstances when NICE considers it
is appropriate for its appraisal committees to apply greater flexibility in their
appraisal of these treatments.</p><p> </p><p> </p><p> </p><p>The advice has now been
incorporated chapter 6 of <em>Guide to the methods of technology appraisal 2013 </em>which
can be found at:</p><p> </p><p> </p><p> </p><p><a href="http://www.nice.org.uk/article/pmg9/chapter/6-the-appraisal-of-the-evidence-and-structured-decision-making"
target="_blank">www.nice.org.uk/article/pmg9/chapter/6-the-appraisal-of-the-evidence-and-structured-decision-making</a></p><p>
</p><p> </p><p> </p>
|
|
